Imatinib Resistance Mechanism on Chronic Myeloid Leukemia
نویسندگان
چکیده
منابع مشابه
Imatinib in chronic myeloid leukemia elderly patients
Leukemia (CML) reported in clinical trials is generally of 50-55 years; it is higher (more than 60 years) in epidemiologic registries and in observational studies [1]. Therefore, a significant proportion of CML patients are " elderly " , according to the most widely accepted definition of " old person " (age > 65 years). Prior to imatinib (IM) introduction, an orally taken tyrosine kinase inhib...
متن کاملImatinib: can one outwit chronic myeloid leukemia?
were most notable in large-sized platelet subpopulations. The implication is that the bleeding tendency in these disorders is secondary to abnormal in vivo platelet-vessel wall and platelet-platelet interactions caused by decreased levels of GPIb-VIX. An interesting finding given the necessary interconnection between cytoskeletal components and membrane proteins. This suggested mechanism deserv...
متن کاملImatinib in Chronic Myeloid Leukemia: an Overview
Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents a BCR-ABL protein from exerting its role in the oncogenic pathway in chronic myeloid leukemia (CML). Imatinib directly inhibits the constitutive tyrosine kinase activity. Imatinib binds to BCR-ABL kinase domain by preventing the transfer of a phosphate group to tyrosine on the protein substrate a...
متن کاملChronic myeloid leukemia in the imatinib era.
The results of imatinib (Gleevec) (formerly STI571) therapy for chronic myeloid leukemia (CML) have continued to improve and have surpassed almost everyone's predictions. However, the long-term results with imatinib and its ability to cure CML as a single agent are unknown. These issues will be discussed along with potential strategies to improve the cure rate, using imatinib as a building bloc...
متن کاملAnalysis of Expression Of SIRT1 Gene In Patients With Chronic Myeloid Leukemia Resistant To Imatinib Mesylate
Background: Chronic myeloid leukemia is a clonal myeloproliferative disease which is characterized by bcr/abl translocation. With the emergence of tyrosine kinase inhibitors such as imatinib mesylate, significant improvement has been made in treatment of this disease. However, drug resistance against this medicine is still an obstacle. SIRT1 is a gene with deacetylase activity which has been de...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: World Journal of Cancer Research
سال: 2012
ISSN: 2164-9049,2164-9057
DOI: 10.12677/wjcr.2012.23003